AFATINIB by Novartis is (erbb1), her2 (erbb2), and her4 (erbb4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of erbb signaling.
Drug data last refreshed 20h ago
(ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on AFATINIB at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Observational Study of Afatinib 30 mg Daily
Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma